Dendritic Cell News and Research

Latest Dendritic Cell News and Research

ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company's clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI.

5 Oct 2010

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Celldex Therapeutics, Inc. today announced that the Company presented initial clinical data on CDX-1401 at the 25th Annual Meeting of the International Society of Biological Therapy of Cancer (iSBTc) in Washington, DC. CDX-1401 is a novel antibody-based targeted cancer vaccine candidate being evaluated as a treatment for patients with melanoma and other cancers that are known to express the tumor antigen NY-ESO-1.

5 Oct 2010

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial.

1 Oct 2010

Clinical study results for patient-specific vaccine therapy to treat metastatic melanoma announced

Hoag Memorial Hospital Presbyterian recently announced encouraging clinical study results for patient-specific vaccine therapy to treat metastatic melanoma. The study is ongoing, but the report concludes that patient-specific vaccines can sometimes induce durable complete regression of progressing soft-tissue melanoma metastases, as demonstrated in one particular patient who participated in the trial.

28 Sep 2010

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

24 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Researchers identify protein essential for dendritic cell development

A protein called PU.1 is essential for the development of dendritic cells, the sentinels of the immune system, Walter and Eliza Hall Institute researchers in Melbourne, Australia, have shown.

20 Sep 2010

ImmunoCellular contracts with Averionto to execution ICT-107 cancer-vaccine Phase II study

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has contracted with the clinical research organization (CRO) Averion International Corp. to conduct its planned Phase II study of ICT-107, the Company's lead cancer-vaccine candidate for the treatment of glioblastoma multiforme (GBM).

17 Sep 2010

Scientists discover sensor in dendritic cells that recognizes HIV

Dendritic cells are the grand sentinels of the immune system, standing guard 24/7 to detect foreign invaders such as viruses and bacteria, and bring news of the invasion to other immune cells to marshal an attack. These sentinels, however, nearly always fail to respond adequately to HIV, the virus causing AIDS. Now a team of scientists at NYU Langone Medical Center has discovered a sensor in dendritic cells that recognizes HIV, spurring a more potent immune response by the sentinels to the virus.

9 Sep 2010

Zebrafish DCs discovery provide researchers to investigate mammalian immune system

Scientists from the University of California, San Diego School of Medicine have identified dendritic antigen presenting cells in zebrafish, opening the possibility that the tiny fish could become a new model for studying the complexities of the human immune system.

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. today announced that treatment with its lead compound, Homspera, in combination with a DNA vaccine utilizing Scancell's ImmunoBody technology significantly improved the immune response of the vaccine in an animal model.

8 Sep 2010

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, announces that a treatment utilising a DNA vaccine based on its ImmunoBody® technology, in combination with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.

7 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Boryung Pharmaceutical implements Cegedim Dendrite's Mobile Intelligence CRM solution

Cegedim Dendrite, the world's leading provider of Life Sciences-specific customer relationship management (CRM) solutions, announced today that Boryung Pharmaceutical Co., Ltd., has implemented Cegedim Dendrite's Mobile Intelligence™ CRM solution. Boryung Pharmaceutical is one of Korea's top 10 domestic pharmaceutical companies, and Cegedim Dendrite currently serves 14 of the industry's top-grossing companies in Korea.

24 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

Single neurons in brain distinguish different temporal sequences of incoming information

Single neurons in the brain are surprisingly good at distinguishing different sequences of incoming information according to new research by UCL neuroscientists.The study, published today in Science and carried out by researchers based at the Wolfson Institute for Biomedical Research at UCL, shows that single neurons, and indeed even single dendrites, the tiny receiving elements of neurons, can very effectively distinguish between different temporal sequences of incoming information.

13 Aug 2010

Cegedim Dendrite, TAKE Solutions form strategic partnership

As part of the Cegedim Dendrite Alliance Program, created to expand its open business model through alliances with leading technology, software and consulting companies, Cegedim Dendrite today announced its partnership in India with TAKE Solutions Ltd.

10 Aug 2010

Cegedim Dendrite, Capgemini to offer software solutions for Life Sciences companies

Cegedim Dendrite, the world's leading provider of pharmaceutical-specific Customer Relationship Management solutions, and Capgemini U.S. LLC ("Capgemini"), one of the world's foremost providers of consulting, technology and outsourcing services, announced an alliance to jointly offer software solutions, consulting and technology services around aggregate spend and customer master data to Life Sciences companies. Through the alliance, Capgemini will provide broad based consulting and implementation services associated with Cegedim Dendrite's AggregateSpend360™ and Nucleus 360™ solutions to pharmaceutical, biotech and medical device companies.

9 Aug 2010

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Argos Therapeutics today announced that its Arcelis immunotherapy targeted at diabetes demonstrated potential for preventing and treating the disease in non-obese diabetic (NOD) mice, according to a peer-reviewed article published in Molecular Therapy.

4 Aug 2010

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

Celldex Therapeutics presents initial clinical data on CDX-1401 cancer vaccine candidate at iSBTc meeting

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Clinical study results for patient-specific vaccine therapy to treat metastatic melanoma announced

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Researchers identify protein essential for dendritic cell development

ImmunoCellular contracts with Averionto to execution ICT-107 cancer-vaccine Phase II study

Scientists discover sensor in dendritic cells that recognizes HIV

Zebrafish DCs discovery provide researchers to investigate mammalian immune system

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmuneRegen's Homspera with Scancell's ImmunoBody technology improves immune response for cancer

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Boryung Pharmaceutical implements Cegedim Dendrite's Mobile Intelligence CRM solution

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

Single neurons in brain distinguish different temporal sequences of incoming information

Cegedim Dendrite, TAKE Solutions form strategic partnership

Cegedim Dendrite, Capgemini to offer software solutions for Life Sciences companies

Arcelis immunotherapy effective in treating autoimmune diseases: Study

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in